Neogen ELISA Drug Detection Kit15-epi-Lipoxin A4 is an aspirin-triggered eicosanoid believed to be involved in the positive attributes of aspirin therapy for heart, cancer and human immunodeficiency virus patients. During inflammation, neutrophils are activated. 15-epi-LXA4, when administered in vivo, inhibits neutrophil activation and dampens inflammation (Takano, 1997). 15-epi-LXA4 is naturally formed in the body via this pathway:
Arachidonic Acid (AA)→15(R) -HETE→15-epi-LXA4

Aspirin is thought to be involved in the acetylation of prostaglandin G/H synthase, which triggers the conversion of AA to 15(R)-HETE. The development of this assay, which is both sensitive and selective for 15-epi-LXA4, will be essential to researchers studying anti-inflammatory medications.

Standard Curve in EIA Buffer

Curve in EIA Buffer

Specificity (Cross-Reactivity)

Analytes Cross-Reactivity
15-epi-Lipoxin A4 100%
Lipoxin A4 3%
15(R)-HETE 0.8%
5(S)-HETE <0.01%
12(S)-HETE <0.01%
15(S)-HETE <0.01%

Specifications

Sensitivity:
   80% B/B0 = 0.05 ng/mL
   50% B/B0 = 0.2 ng/mL
Assay Range: 0.2 - 2.0 ng/mL
Inter-Assay CV: ≤ 10%
Intra-Assay CV: ≤ 10%
Size: 96 well microplate
Assay Sample Size: 50 µL
Total Assay Incubation Time: 1.5 hours
Wavelength: 650 nm, 450 nm with acid stop
Storage Conditions: -20°C for lyophilized conjugate, 4°C for all other kit components
Antibody: Polyclonal, Rabbit

Order Details

Product # Product Description
407110 15-epi-Lipoxin A4, 96 well kit

Reference Materials

Kit inserts available on our website are for reference use only and are subject to change. It is always recommended to use the protocol included with the kit.

For research use only.